Find out about the diseases and illnesses we specialise in

Polycythaemia Vera

Policitemia vera a Vall d'Hebron

A rare slow-growing chronic blood cancer. It is mainly characterised by increased production of red blood cells, associated with greater risk of clotting, both in veins and in arteries. It has non-specific symptoms, such as increased facial redness and bodily itching. Although there is currently no cure, it can be effectively controlled.



It is included within the group of chronic myeloproliferative disorders. Its cause is not known, although there are known mutations associated with it in the JAK2 gene that occur in 98% of cases. It is not hereditary, but some families may have several members affected by it.

It is characterised by increased production of red blood cells (the number of white blood cells and platelets may also go up) and is associated with increased risk of clotting in arteries or veins.

It is a chronic disease, which cannot currently be cured. It can be effectively controlled over long periods and generally has little impact on daily activities and work. Patients with this condition have increased risk compared to the general population of developing other blood diseases, such as acute leukaemia or myelofibrosis.



There may initially be no symptoms. Facial redness is characteristic of this condition. Patients often present with tiredness, headaches, dizziness and itching (particularly after showering). They may also experience abdominal pain due to increased spleen size.


How is affected by the condition ? 

It mainly affects patients around 60 years old and is a little more common in men than in women.



Mainly done through an analysis revealing high levels of haemoglobin and haematocrits. The number of platelets and white blood cells may also be elevated. A molecular test is also sometimes conducted (JAK2 gene mutation). Other tests may sometimes be needed to complete the diagnosis, such as a bone marrow biopsy.


Typical treatment

Treatment aims to prevent complications and control symptoms. It is based on decreasing excess red blood cells by phlebotomies (blood extractions performed in the blood bank). Except for some contraindications, patients require antiplatelets (acetylsalicylic acid). Other drugs to reduce red blood cells may also be indicated.


Typical tests 

It is usually controlled by analysis. 



The most important thing is preventing clotting complications associated with this condition by controlling cardiovascular risk factors (high blood pressure, dyslipidaemia, smoking, obesity, sedentary lifestyle) and following the treatment recommended by your haematologist. 








Hospital o serveis complementaris relacionats

General Hospital

Where to find it
Related professionals
Dr. Josep
Tabernero Caturla
Head of Department
Medical Oncology
Dra. Enriqueta
Head of Section
Medical Oncology
Lead Researcher
Thoracic tumours and head and neck cancer group
Dr. César
Serrano García
Medical Oncology
Lead Researcher
Genitourinary, Central Nervous System (CNS) Tumours, Sarcoma and cancer of unknown primary site programme
Dr. Joan
Carles Galcerán
Head of Section
Medical Oncology
Lead Researcher
Genitourinary, Central Nervous System (CNS) Tumours, Sarcoma and cancer of unknown primary site programme
Dra. Cristina
Saura Manich
Head of Unit
Medical Oncology
Clinical Researcher
Breast cancer and melanoma group
Dra. Teresa
Macarulla Mercadé
Medical Oncology
Dr. David
Beneitez Pastor
Sra. Sandra
Sra. Nuria
González Pedrero
Sr. Lluís
Peña Garcia
Medical Oncology